Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 7/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258543 | 0.75 | NOTUM (0.56) | MTNR1AMTNR1BHTR2AGPR84 | |
| SCHEMBL21562520 | 0.75 | MTNR1A (0.39) | TDO2MTNR1AMTNR1BHTR2AGPR84 | |
| SCHEMBL6469180 | 0.75 | HTR2A (0.62) | TDO2NR3C1HTR2AHTR2CGPR84 | |
| Hydrochloric Acid SCHEMBL21546051 | 0.73 | HTR2A (0.60) | TDO2NR3C1HTR2AHTR2CGPR84 | |
| SCHEMBL27524772 | 0.72 | GPR84 (0.42) | TDO2NR3C1HTR2AHTR2CGPR84 | |
| SCHEMBL20258542 | 0.71 | HTR2A (0.60) | MTNR1AMTNR1BNR3C1HTR2AHTR2C | |
| SCHEMBL12950449 | 0.70 | GPR84 (0.53) | TDO2HTR2AHTR2CGPR84 | |
| SCHEMBL31158762 | 0.70 | GPR84 (0.53) | TDO2HTR2AHTR2CGPR84 | |
| SCHEMBL20258597 | 0.68 | NOTUM (0.70) | MTNR1AMTNR1BHTR2A | |
| SCHEMBL21562489 | 0.68 | HTR1A (0.56) | HTR2AHTR2CGPR84HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2019-11-14 | — | — | US | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | TDO2 2267/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | TDO2 2267/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | TDO2 2267/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.